Spyre Therapeutics Inc’s filing revealed that its Director Albers Jeffrey W. unloaded Company’s shares for reported $0.25 million on Nov 06 ’24. In the deal valued at $36.76 per share,6,700 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 27,360 shares worth roughly $0.35 million.
Then, Albers Jeffrey W. sold 300 shares, generating $10,929 in total proceeds. Upon selling the shares at $36.43, the Director now owns 34,060 shares.
Before that, SESSIONS, LLC bought 7,000 shares. Spyre Therapeutics Inc shares valued at $235,900 were divested by the Director at a price of $33.70 per share.
Leerink Partners initiated its Spyre Therapeutics Inc [SYRE] rating to an Outperform in a research note published on April 08, 2025; the price target was $45. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Wedbush began covering SYRE with “an Outperform” recommendation on September 04, 2024. Evercore ISI started covering the stock on July 16, 2024. It rated SYRE as “an Outperform”.
Price Performance Review of SYRE
On Tuesday, Spyre Therapeutics Inc [NASDAQ:SYRE] saw its stock fall -2.38% to $12.71. Over the last five days, the stock has gained 7.71%. Spyre Therapeutics Inc shares have fallen nearly -45.40% since the year began. Nevertheless, the stocks have fallen -66.10% over the past one year. While a 52-week high of $40.49 was reached on 01/07/25, a 52-week low of $10.91 was recorded on 04/09/25. SMA at 50 days reached $18.49, while 200 days put it at $25.38.
Levels Of Support And Resistance For SYRE Stock
The 24-hour chart illustrates a support level at 12.42, which if violated will result in even more drops to 12.14. On the upside, there is a resistance level at 13.14. A further resistance level may holdings at 13.57. The Relative Strength Index (RSI) on the 14-day chart is 35.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.56%. Stochastics %K at 22.17% indicates the stock is a holding.
How much short interest is there in Spyre Therapeutics Inc?
A steep rise in short interest was recorded in Spyre Therapeutics Inc stocks on 2025-03-31, growing by 1.34 million shares to a total of 11.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 10.02 million shares. There was a rise of 11.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 02, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
